Results 21 to 30 of about 244,171 (297)

Combination of Silibinin and Curcumin Reduced Leptin Receptor Expression in MCF-7 Human Breast Cancer Cell Line [PDF]

Iranian Journal of Medical Sciences, 2020
Background: Leptin and leptin receptor (Ob-R) are associated with worse prognosis, distant metastasis, and poor survival of breast cancer. We investigated the cytotoxic effect of silibinin and curcumin, individually and combined, on Ob-R expression in ...
Somaye Dalimi-Asl, Hossein Babaahmadi-Rezaei, Ghorban Mohammadzadeh   +2 more
doaj   +1 more source

The efficacy of calcitriol treatment in non-alcoholic fatty liver patients with different genotypes of vitamin D receptor FokI polymorphism

BMC Pharmacology and Toxicology, 2021
Background Vitamin D deficiency is prevalent in patients with non-alcoholic fatty liver disease (NAFLD), but there are debates on the usefulness of vitamin D treatment.
Hamid Yaghooti, Fatemeh Ghanavati, Seyed Saeed Seyedian, Bahman Cheraghian, Narges Mohammadtaghvaei   +4 more
doaj   +1 more source

Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions

Journal of Lipid Research, 1997
In order to assess the relationship between plasma accumulation of triglyceride-rich lipoproteins (TRL) and lipoprotein levels of apoC-III and apoE, we have measured apoC-III and apoE in lipoproteins separated according to size (by automated gel ...
A Fredenrich, L M Giroux, M Tremblay, L Krimbou, J Davignon, J S Cohn   +5 more
doaj   +1 more source

Hyperglycemia and Hyperlipidemia Act Synergistically to Induce Renal Disease in LDL Receptor-Deficient BALB Mice [PDF]

, 2004
Diabetic nephropathy is the leading cause of end-stage renal disease in Western countries, but only a portion of diabetic patients develop diabetic nephropathy.
Alpers, Charles E., Hudkins, Kelly L., Kirk, Elizabeth, LeBoeuf, Renée C., Mühlfeld, Anja S., Segerer, Stephan, Spencer, Min W.   +6 more
core   +1 more source

Therapy of Canine Hyperlipidemia with Bezafibrate. [PDF]

, 2017
BackgroundBezafibrate (BZF) is effective in the treatment of hypertriglyceridemia in human patients, but there are no data on its use in dogs.ObjectiveTo assess the safety of BZF in hyperlipidemic dogs and its efficacy in decreasing serum triglyceride ...
Casado, TC, De Marco, V, Florio, JC, Gilor, C, Nakandakare, ER, Noronha, KSM, Santos, EZ   +6 more
core   +1 more source

Characterization of human plasma apolipoprotein E-containing lipoproteins in the high density lipoprotein size range: focus on pre-beta1-LpE, pre-beta2-LpE, and alpha-LpE.

Journal of Lipid Research, 1997
We have used two-dimensional gel electrophoresis to separate and characterize human plasma apolipoprotein (apo) E-containing lipoproteins in the high density lipoprotein (HDL) size range.
L Krimbou, M Tremblay, J Davignon, J S Cohn   +3 more
doaj   +1 more source

The Correlation of Dyslipidemia with the Extent of Coronary Artery Disease in the Multiethnic Study of Atherosclerosis. [PDF]

, 2018
BackgroundThe extent of coronary artery calcium (CAC) improves cardiovascular disease (CVD) risk prediction. The association between common dyslipidemias (combined hyperlipidemia, simple hypercholesterolemia, metabolic Syndrome (MetS), isolated low high ...
Abd Alamir, Moshrik, Brown, Alan, Budoff, Mathew, Chaus, Adib, Dabbous, Firas, Goyfman, Michael, Sandfort, Veit, Tamura, Leslie   +7 more
core   +4 more sources

Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects

Journal of Lipid Research, 2000
Apolipoprotein (apo) C-III and apoE play a central role in controlling the plasma metabolism of triglyceride-rich lipoproteins (TRL). We have investigated the plasma kinetics of total, very low density lipoprotein (VLDL) and high density lipoprotein (HDL)
Rami Batal, Michel Tremblay, P. Hugh R. Barrett, Hélène Jacques, Alexandre Fredenrich, Orval Mamer, Jean Davignon, Jeffrey S. Cohn   +7 more
doaj   +1 more source

Apolipoprotein E and Atherosclerosis: From Lipoprotein Metabolism to MicroRNA Control of Inflammation. [PDF]

, 2018
Apolipoprotein (apo) E stands out among plasma apolipoproteins through its unprecedented ability to protect against atherosclerosis. Although best recognized for its ability to mediate plasma lipoprotein clearance in the liver and protect against ...
Hasty, Hui, Hussain, Lin, Mahley, Pepe, Roselaar   +6 more
core   +2 more sources

Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans

Journal of Lipid Research, 2003
Numerous factors are known to affect the plasma metabolism of HDL, including lipoprotein receptors, lipid transfer protein, lipolytic enzymes and HDL apolipoproteins.
Jeffrey S. Cohn, Rami Batal, Michel Tremblay, Hélène Jacques, Lyne Veilleux, Claudia Rodriguez, Orval Mamer, Jean Davignon   +7 more
doaj   +1 more source